Page 49 - 2019_03-Haematologica-web

IgG4-related disease for hematologists
observations in a study of 303 cases. Am J
Clin Pathol. 2016;146(3):303-311.
40. McCudden CR, Jacobs JFM, Keren D, Caillon H, Dejoie T, Andersen K. Recognition and management of common, rare, and novel serum protein electrophore- sis and immunofixation interferences. Clin
Biochem. 2017;51:72-79.
41. Dispenzieri A, Gertz MA, Therneau TM,
Kyle RA. Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc. 2001;76(5):476-487.
42. Zhao EJ, Carruthers MN, Li CH, Mattman A, Chen LYC. Prevalence of IgG4-Related Disease in Patients with Hypergammaglobulinemia. XXXVII World Congress of the International Society of Hematology (ISH 2018); Sept 14, 2018, 2018; Vancouver, British Columbia, Canada.
43. Engelhart S, Glynn RJ, Schur PH. Disease associations with isolated elevations of each of the four IgG subclasses. Semin Arthritis Rheum. 2017;47(2):276-280.
44. Zheng M, Zhou P, Zheng K, et al. A special subtype of POEMS syndrome: IgG4 sub- type. Am J Transl Res. 2016;8(2):588-596.
45. Zhu J, Wu B. Immunoglobulin G4-positive plasma cell myeloma. Blood. 2015;126(19): 2254.
46. Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4- related disease. Lancet. 2014;385(9976): 1460-1471.
47. Zhang X, Hyjek E, Vardiman J. A subset of Rosai-Dorfman disease exhibits features of IgG4-related disease. Am J Clin Pathol. 2013;139(5):622-632.
48. Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672-2681.
49. Abla O, Jacobsen E, Picarsic J, et al. Consensus recommendations for the diag- nosis and clinical management of Rosai- Dorfman-Destombes disease. Blood. 2018;131(26):2877-2890.
50. Deshpande V, Khosroshahi A, Nielsen GP, Hamilos DL, Stone JH. Eosinophilic angio- centric fibrosis is a form of IgG4-related sys- temic disease. Am J Surg Pathol. 2011;35(5):701-706.
51. Estrada-Veras JI, O'Brien KJ, Boyd LC, et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 2017;1(6):357-366.
52. Sato Y, Ohshima K, Ichimura K, et al. Ocular adnexal IgG4-related disease has uniform clinicopathology. Pathol Int. 2008;58(8):465- 470.
53. Bledsoe JR, Wallace ZS, Stone JH, Deshpande V, Ferry JA. Lymphomas in IgG4-related disease: clinicopathologic fea- tures in a Western population. Virchows Arch. 2017;472(5):839-852.
54. van de Ven A, Seidl M, Drendel V, et al. IgG4-related disease in autoimmune lym- phoproliferative syndrome. Clin Immunol. 2017;180:97-99.
55. Langan RC, Gill F, Raiji MT, et al. Autoimmune pancreatitis in the autoim- mune lymphoproliferative syndrome (ALPS): a sheep in wolves' clothing? Pancreas. 2013;42(2):363-366.
56. Carruthers MN, Stone JH, Deshpande V, Khosroshahi A. Development of an IgG4-
RD Responder Index. Int J Rheumatol.
2012;2012:259408.
57. Wallace ZS, Khosroshahi A, Carruthers MD,
et al. An international, multi-specialty vali- dation study of the IgG4-related disease responder index. Arthritis Care Res (Hoboken). 2018;70(11):1671-1678.
58. Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH. The diagnostic util- ity of serum IgG4 concentrations in IgG4- related disease. Ann Rheum Dis. 2015;74(1):14-18.
59. Culver EL, Sadler R, Simpson D, et al. Elevated serum IgG4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective IgG4-related disease UK cohort. Am J Gastroenterol. 2016;111 (5):733-743.
60. Masaki Y, Kurose N, Yamamoto M, et al. Cutoff values of serum IgG4 and histopathological IgG4+ plasma cells for diagnosis of patients with IgG4-related dis- ease. Int J Rheumatol. 2012;2012:580814.
61. Qi R, Chen LYC, Park S, et al. Utility of serum IgG4 levels in a multiethnic population. Am J Med Sci. 2018;355(1):61-66.
62. Wallace ZS, Mattoo H, Carruthers M, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concen- trations. Ann Rheum Dis. 2015;74(1):190- 195.
63. Parker AR, Carr-Smith HD. Calibration dif- ferences and the prozone phenomenon in IgG4-related disease: comment on the article by Khosroshahi et al. Arthritis Rheumatol. 2014;66(7):1964-1965.
64. Khosroshahi A, Cheryk LA, Carruthers MN, Edwards JA, Bloch DB, Stone JH. Brief Report: spuriously low serum IgG4 concen- trations caused by the prozone phenome- non in patients with IgG4-related disease. Arthritis Rheumatol. 2014;66(1):213-217.
65. van der Gugten G, DeMarco ML, Chen LYC, et al. Resolution of spurious immunonephelometric IgG subclass meas- urement discrepancies by LC-MS/MS. Clin Chem. 2018;64(4):735-742.
66. Chan ASY, Mudhar H, Shen SY, et al. Serum IgG2 and tissue IgG2 plasma cell elevation in orbital IgG4-related disease (IgG4-RD): potential use in IgG4-RD assessment. Br J Ophthalmol. 2017;101(11):1576-1582.
67. Dunkley L, Mudhar HS. IgG4-related dis- ease presenting with raised serum IgG2-real timeline of IgG4-RD? Rheumatology. 2017;57(1):197-199.
68. Mattman A, Chen LYC, van der Gugten G, et al. Comment on: IgG4-related disease presenting with raised serum IgG2-real timeline of IgG4-RD? Rheumatology. 2018;57(6):1126-1127.
69. Chari ST, Takahashi N, Levy MJ, et al. A diagnostic strategy to distinguish autoim- mune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol. 2009;7(10): 1097-1103.
70. Mann S, Seidman MA, Barbour SJ, Levin A, Carruthers M, Chen LY. Recognizing IgG4- related tubulointerstitial nephritis. Can J Kidney Health Dis. 2016;3:34.
71. Moriyama M, Ohta M, Furukawa S, et al. The diagnostic utility of labial salivary gland biopsy in IgG4-related disease. Mod Rheumatol. 2016;26(5):725-729.
72. Arora K, Rivera M, Ting DT, Deshpande V. The histologic diagnosis of IgG4-related dis- ease on small biopsies: challenges and pit- falls. Histopathology. 2018 Nov 8. [Epub ahed of print]
73. Kuo TT, Chen TC, Lee LY. Sclerosing angiomatoid nodular transformation of the spleen (SANT): clinicopathological study of 10 cases with or without abdominal dissemi- nated calcifying fibrous tumors, and the pres- ence of a significant number of IgG4+ plasma cells. Pathol Int. 2009;59(12):844-850.
74. Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171-1177.
75. Wallace ZS, Khosroshahi A, Jakobiec FA, et al. IgG4-related systemic disease as a cause of "idiopathic" orbital inflammation, includ- ing orbital myositis, and trigeminal nerve involvement. Surv Ophthalmol. 2012;57(1): 26-33.
76. Ebbo M, Grados A, Guedj E, et al. Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomogra- phy for staging and evaluation of treatment response in IgG4-related disease: a retrospec- tive multicenter study. Arthritis Care Res (Hoboken). 2014;66(1):86-96.
77. Masaki Y, Matsui S, Saeki T, et al. A multi- center phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease. Mod Rheumatol. 2017;27(5):849-854.
78. Wang L, Zhang P, Wang M, et al. Failure of remission induction by glucocorticoids alone or in combination with immunosup- pressive agents in IgG4-related disease: a prospective study of 215 patients. Arthritis Res Ther. 2018;20(1):65.
79. Masamune A, Nishimori I, Kikuta K, et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut. 2017;66(3):487-494.
80. Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancre- atitis with immunomodulators and ritux- imab: the Mayo Clinic experience. Gut. 2013;62(11):1607-1615.
81. Yunyun F, Yu C, Panpan Z, et al. Efficacy of cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids. Sci Rep. 2017;7(1):6195.
82. Yunyun F, Yu P, Panpan Z, et al. Efficacy and safety of low dose mycophenolate mofetil treatment for immunoglobulin G4-related disease. Rheumatology (Oxford, England). 2018 Aug 14. [Epub ahead of print].
83. Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4- related disease. Arthritis Rheumatol. 2015;67(7):1688-1699.
84. Ebbo M, Grados A, Samson M, et al. Long- term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS One. 2017;12(9):e0183844.
85. Stone JH, Wallace ZS, Perugino CA, et al. A Trial of XmAb (R) 5871, a reversible inhibitor of CD19+ cells, in IgG4-related disease. Arthritis Rheumatol. 2016;68(Suppl 10).
haematologica | 2019; 104(3)
455